Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
The body does not retroactively make up for months of poor absorption
It is considered an experimental compound and therefore the decision is made between you and your doctor whether this is the right treatment for you
6 However, GLP-1 receptor agonists and gut-derived GLP-1 do not cross the bloodbrain barrier and cannot access GLP-1 receptors in the brain parenchyma, which can only be accessed by brain (pre-proglucagon neuron)-derived GLP-1
Using medical-grade peptides that work at the cellular level, this treatment helps restore balance, boost energy, and promote natural healing throughout the body
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025
Anden, N
US$ 22.19
US$ 21.86
US$ 20.41
US$ 26.93
US$ 24.68
US$ 27.08
US$ 25.67
US$ 20.64